Medical - Vaccine Guide 2022 - 25

Notes
Recommended Adult Immunization Schedule, United States, 2022
y Pregnancy: Delay MenB until after pregnancy unless at
increased risk and vaccination benefits outweigh potential
risks
y For MenB booster dose recommendations for groups
listed under " Special situations " and in an outbreak
setting (e.g., in community or organizational settings
and among men who have sex with men) and additional
meningococcal vaccination information, see www.cdc.gov/
mmwr/volumes/69/rr/rr6909a1.htm
Note: MenB vaccines may be administered simultaneously
with MenACWY vaccines if indicated, but at a different
anatomic site, if feasible.
Pneumococcal vaccination
Routine vaccination
y Age 65 years or older who have not previously received
a pneumococcal conjugate vaccine or whose previous
vaccination history is unknown: 1 dose PCV15 or 1 dose
PCV20. If PCV15 is used, this should be followed by a
dose of PPSV23 given at least 1 year after the PCV15
dose. A minimum interval of 8 weeks between PCV15
and PPSV23 can be considered for adults with an
immunocompromising condition,* cochlear implant, or
cerebrospinal fluid leak to minimize the risk of invasive
pneumococcal disease caused by serotypes unique to
PPSV23 in these vulnerable groups.
y For guidance for patients who have already received a
previous dose of PCV13 and/or PPSV23, see
www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm.
Special situations
y Age 19-64 years with certain underlying medical
conditions or other risk factors** who have not previously
received a pneumococcal conjugate vaccine or whose
previous vaccination history is unknown: 1 dose PCV15
or 1 dose PCV20. If PCV15 is used, this should be followed
by a dose of PPSV23 given at least 1 year after the
PCV15 dose. A minimum interval of 8 weeks between
PCV15 and PPSV23 can be considered for adults with an
immunocompromising condition,* cochlear implant, or
cerebrospinal fluid leak to minimize the risk of invasive
pneumococcal disease caused by serotypes unique to
PPSV23 in these vulnerable groups.
y For guidance for patients who have already received a
previous dose of PCV13 and/or PPSV23, see
www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm.
*Note: Immunocompromising conditions include chronic
renal failure, nephrotic syndrome, immunodeficiency,
iatrogenic immunosuppression, generalized malignancy,
human immunodeficiency virus, Hodgkin disease, leukemia,
lymphoma, multiple myeloma, solid organ transplants,
congenital or acquired asplenia, sickle cell disease, or other
hemoglobinopathies.
**Note: Underlying medical conditions or other risk
factors include alcoholism, chronic heart/liver/lung
disease, chronic renal failure, cigarette smoking, cochlear
implant, congenital or acquired asplenia, CSF leak, diabetes
mellitus, generalized malignancy, HIV, Hodgkin disease,
immunodeficiency, iatrogenic immunosuppression,
leukemia, lymphoma, multiple myeloma, nephrotic
syndrome, solid organ transplants, or sickle cell disease or
other hemoglobinopathies.
Tetanus, diphtheria, and pertussis vaccination
Routine vaccination
y Previously did not receive Tdap at or after age 11 years:
1 dose Tdap, then Td or Tdap every 10 years
Special situations
y Previously did not receive primary vaccination series
for tetanus, diphtheria, or pertussis: 1 dose Tdap
followed by 1 dose Td or Tdap at least 4 weeks after Tdap
and another dose Td or Tdap 6-12 months after last Td
or Tdap (Tdap can be substituted for any Td dose, but
preferred as first dose), Td or Tdap every 10 years thereafter
y Pregnancy: 1 dose Tdap during each pregnancy, preferably
in early part of gestational weeks 27-36
yWound management: Persons with 3 or more doses of
tetanus-toxoid-containing vaccine: For clean and minor
wounds, administer Tdap or Td if more than 10 years since
last dose of tetanus-toxoid-containing vaccine; for all other
wounds, administer Tdap or Td if more than 5 years since
last dose of tetanus-toxoid-containing vaccine. Tdap is
preferred for persons who have not previously received
Tdap or whose Tdap history is unknown. If a tetanus-toxoidcontaining
vaccine is indicated for a pregnant woman, use
Tdap. For detailed information, see www.cdc.gov/mmwr/
volumes/69/wr/mm6903a5.htm
Varicella vaccination
Routine vaccination
y No evidence of immunity to varicella: 2-dose series 4-8
weeks apart if previously did not receive varicella-containing
vaccine (VAR or MMRV [measles-mumps-rubella-varicella
vaccine] for children); if previously received 1 dose varicellacontaining
vaccine, 1 dose at least 4 weeks after first dose
2/17/2022
22MS6015
25
Centers for Disease Control and Prevention | Recommended Adult Immunization Schedule, United States, 2022
henryschein.com/medical
- Evidence of immunity: U.S.-born before 1980 (except for
pregnant women and health care personnel [see below]),
documentation of 2 doses varicella-containing vaccine
at least 4 weeks apart, diagnosis or verification of history
of varicella or herpes zoster by a health care provider,
laboratory evidence of immunity or disease
Special situations
y Pregnancy with no evidence of immunity to varicella:
VAR contraindicated during pregnancy; after pregnancy
(before discharge from health care facility), 1 dose if
previously received 1 dose varicella-containing vaccine
or dose 1 of 2-dose series (dose 2: 4-8 weeks later) if
previously did not receive any varicella-containing vaccine,
regardless of whether U.S.-born before 1980
y Health care personnel with no evidence of immunity
to varicella: 1 dose if previously received 1 dose varicellacontaining
vaccine; 2-dose series 4-8 weeks apart if
previously did not receive any varicella-containing vaccine,
regardless of whether U.S.-born before 1980
y HIV infection with CD4 percentages ≥15% and CD4
count ≥200 cells/mm3
y Severe immunocompromising conditions: VAR
contraindicated
Zoster vaccination
Routine vaccination
y Age 50 years or older: 2-dose series RZV (Shingrix) 2-6
months apart (minimum interval: 4 weeks; repeat dose
if administered too soon), regardless of previous herpes
zoster or history of zoster vaccine live (ZVL, Zostavax)
vaccination (administer RZV at least 2 months after ZVL)
Special situations
y Pregnancy: There is currently no ACIP recommendation
for RZV use in pregnancy. Consider delaying RZV until after
pregnancy.
y Immunocompromising conditions (including HIV): RZV
recommended for use in persons age 19 years or older
who are or will be immunodeficient or immunosuppressed
because of disease or therapy. For detailed information, see
www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm.
with no evidence of immunity:
Vaccination may be considered (2 doses 3 months apart);
VAR contraindicated for HIV infection with CD4 percentage
<15% or CD4 count <200 cells/mm3
http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm http://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm http://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm http://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm http://www.cdc.gov/mmwr/volumes/71/wr/mm7103a2.htm http://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm http://www.henryschein.com/medical
Medical - Vaccine Guide 2022

Table of Contents for the Digital Edition of Medical - Vaccine Guide 2022
